Beyond R-CHOP, targeting BCR signaling with inhibitors of Btk, Syk, or the phosphoinositide 3-kinase/Akt/mTOR pathway, as well as targeting pro-survival oncoproteins such as Bcl2, has shown efficacy as monotherapies for DLBCL (42). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.